AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference

Guía de Regalos

MASON, Ohio–(BUSINESS WIRE)–AtriCure,
Inc.
(Nasdaq:ATRC),
a leading innovator in treatments for atrial fibrillation (Afib) and
left atrial appendage (LAA) management, today announced that it will
present at the 35th Annual JP Morgan Healthcare Conference at
the Westin St. Francis Hotel in San Francisco on Thursday, January 12,
2017. Management is scheduled to present at 9:30 a.m. Pacific Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.

About AtriCure

AtriCure, Inc. is a medical device company that provides innovative
solutions designed to decrease the global Afib epidemic. AtriCure’s
Isolator® Synergy™ Ablation System is the first and only surgical device
approved for the treatment of persistent and longstanding persistent
forms of Afib in patients undergoing certain open concomitant
procedures. AtriCure’s AtriClip® Left Atrial Appendage Management (LAAM)
exclusion device is the most widely sold device worldwide that is
indicated for the occlusion of the left atrial appendage. AtriCure
believes electrophysiologists and cardiothoracic surgeons are adopting
its technologies for the treatment of Afib and reduction of Afib related
complications. Afib affects more than 33 million people worldwide. For
more information, visit AtriCure.com
or follow us on Twitter @AtriCure.

Contacts

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President
and Chief Financial Officer
awade@atricure.com
or
Gilmartin
Group
Lynn Pieper Lewis, 415-937-5402
Investor Relations
lynn@gilmartinir.com